InvestmentJul 24, 2026, 06:36 AM
MannKind Raises $50M in Private Placement
AI Summary
MannKind Corporation announced it has entered into a securities purchase agreement for a private placement with certain institutional investors, led by Frazier Life Sciences. The financing is expected to generate gross proceeds of approximately $50 million. The company intends to use the net proceeds for general corporate purposes, including funding a $45 million contingent value rights payment triggered by the recent FDA approval of Furoscix ReadyFlow™. The private placement involves the sale of common stock and pre-funded warrants.
Key Highlights
- Gross proceeds from private placement expected to be approximately $50 million.
- Selling 10,440,838 shares of common stock and 2,412,632 pre-funded warrants.
- Purchase price of $3.89 per share and $3.88 per pre-funded warrant.
- Pre-funded warrants have an exercise price of $0.01 per share.
- Net proceeds to fund $45 million contingent value rights payment.
- Net proceeds also for general corporate purposes.
Price Impact
More from MNKD